36 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. As a leader in cancer
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY
29 Apr 24
."
"Bristol Myers Squibb strives to change the treatment paradigm for patients with autoimmune and immune-mediated diseases with a commitment
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
ABBV
ATNM
AZN
19 Apr 24
results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements
ki6fhwyde 5w2wxqvcn3wk48u
ATNM
AZN
BMY
17 Apr 24
the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking
yxslmh5us xaprt
BMY
6 Apr 24
and healthcare systems. At Bristol Myers Squibb, we are committed to advancing our robust pipeline of potential medicines for neurological disorders
igd2h32a92t3cumlm0wh2
BMY
TSVT
5 Apr 24
myeloma, underscoring BMS' commitment to delivering Abecma globally, with consistently high manufacturing
cwzv2
BMY
TSVT
5 Apr 24
for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS' commitment to delivering
b2gueq0lwdwdxypvrg9s68f2gkbromiytotzci4y3fi22l0 s5hvvz6i22
BMY
2 Apr 24
president and head of European Markets, Bristol Myers Squibb. "This milestone underscores our ongoing commitment to developing new options for patients
whlngok27xse6if124gt0kcp8jytnq1b4
BMY
2 Apr 24
is committed to advancing sustainability."
In 2023, BMS conducted a global
s74mqd5q ajhpbzxfwe
BMY
CATX
LNTH
28 Mar 24
Commitments
xynp5
BMY
25 Mar 24
(the Alliance) is committed to driving education and awareness about atrial fibrillation and deep vein thrombosis (DVT) and/or pulmonary embolism (PE). With long